



an Open Access Journal by MDPI

Measles-Mumps-Rubella-Varicella Vaccination

Guest Editor:

Prof. Dr. Silvio Tafuri

Department of Biomedical
Science and Human Oncology,
Aldo Moro University of Bari,
Piazza Giulio Cesare 11, 70124
Bari, Italy

Deadline for manuscript
submissions:

closed (1 February 2021)

Message from the Guest Editor

Dear Colleagues,

According to the Global Vaccine Action Plan, measles and rubella are targeted for elimination in five WHO Regions by 2020. This goal, established in 2015, has been postponed and probably will be delayed, according to the actual world epidemiological scenario.

Global measles deaths have declined from 550,100 deaths in 2000 to 89,780 deaths in 2016. Furthermore, we noted a very important resurgence of this disease; WHO statistics showed over 112,000 confirmed measles cases globally in the first 4 months of 2019. Europe has also seen a 300% increase in measles infection, with Italy and the German state of Brandenburg ordering mandatory vaccinations.

Prof. Silvio Tafuri
Guest Editor



mdpi.com/si/37980

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)